The present invention is related to a radiolabeled active targeting pharmaceutical composition, comprising: a bioconjugate and a radionuclide, wherein the bioconjugate comprises a biomolecule and a metal nanoparticle, wherein the biomolecule has a high affinity for receptors on membrane and is selected from the group consisting of a peptide and a protein. A method for evaluating the thermal adjuvant therapy for tumors and the kit thereof are also provided herein. According to the method, the above-mentioned pharmaceutical composition is applied to evaluate the tumor accumulation time, and the optimal policy for radiofrequency- or laser-induced thermal adjuvant therapy will be constructed as the time data obtained.
